NO971683L - Lyofilisert farmasöytisk preparat som gjör vandige medikamentblandinger reversibelt termogelatinerende - Google Patents

Lyofilisert farmasöytisk preparat som gjör vandige medikamentblandinger reversibelt termogelatinerende

Info

Publication number
NO971683L
NO971683L NO971683A NO971683A NO971683L NO 971683 L NO971683 L NO 971683L NO 971683 A NO971683 A NO 971683A NO 971683 A NO971683 A NO 971683A NO 971683 L NO971683 L NO 971683L
Authority
NO
Norway
Prior art keywords
reversible
freeze
pharmaceutical preparation
gelatinization
thermogelatin
Prior art date
Application number
NO971683A
Other languages
English (en)
Other versions
NO971683D0 (no
Inventor
Masanobu Takeuchi
Hiroe Suzuki
Toshie Takahashi
Hiroki Muruyama
Miyako Sasaki
Keiko Naito
Touro Oguma
Makoto Maeda
Original Assignee
Wakamoto Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakamoto Pharma Co Ltd filed Critical Wakamoto Pharma Co Ltd
Publication of NO971683D0 publication Critical patent/NO971683D0/no
Publication of NO971683L publication Critical patent/NO971683L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Abstract

Frysetørket farmasøytisk preparat fremstilt ved å frysetørke en vandig bland- ing som har egenskapen reversibel varm- herdende gelatinering, oinfattende en effektiv mengde av et medikament, 0,2-2,1 vekt/vol% metylcellulose (metoksylgruppe-innhold i området 26-33%), 1,2-2,3 vekt/vol% sitronsyre og 0,5-13 vekt/vol% polyetylenglykol (PEG). Det frysetørkede farmasøytiske preparat muliggjør stabil lagring av medikamenter som er ustabile overfor vann, inntil de kan tas i praktisk bruk. Ved terapeutisk anvendelse kan preparat- et umiddelbart rekonstitueres ved til- f^r:i-f-r^ i !^^^1 *^..- stituering slik at det oppnås en vandig blanding som har egenskapen reversibel, varmherdende gelatinering, og den undergår gelatinering ved påføring lokalt.
NO971683A 1994-10-13 1997-04-11 Lyofilisert farmasöytisk preparat som gjör vandige medikamentblandinger reversibelt termogelatinerende NO971683L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1994/001709 WO1996011672A1 (fr) 1994-10-13 1994-10-13 Preparation lyophilisee permettant d'obtenir une composition pharmaceutique a base d'eau se transformant de maniere reversible en gel sous l'effet de la chaleur

Publications (2)

Publication Number Publication Date
NO971683D0 NO971683D0 (no) 1997-04-11
NO971683L true NO971683L (no) 1997-06-12

Family

ID=14098719

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971683A NO971683L (no) 1994-10-13 1997-04-11 Lyofilisert farmasöytisk preparat som gjör vandige medikamentblandinger reversibelt termogelatinerende

Country Status (6)

Country Link
US (1) US5756552A (no)
EP (1) EP0782850A4 (no)
KR (1) KR100215739B1 (no)
FI (1) FI971533A (no)
NO (1) NO971683L (no)
WO (1) WO1996011672A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
BR9908692A (pt) * 1998-03-09 2001-12-04 Ista Pharmaceuticals Inc Uso de agentes de enrijecimento corneal emortocerotologia enzimática
US6458341B1 (en) * 1998-06-04 2002-10-01 3M Innovative Properties Company Devices with coatings containing chlorhexidine gluconate, compositions and methods
ES2155027B1 (es) * 1999-05-24 2001-12-01 Univ Pais Vasco Geles para propositos multiples, reversibles y degradables.
AU2231601A (en) * 1999-12-28 2001-07-09 Meiji Seika Kaisha Ltd. Vancomycin preparations
US6413537B1 (en) * 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US20050080043A1 (en) * 2000-09-20 2005-04-14 Lee Shahinian Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
SE0401321D0 (sv) * 2004-05-25 2004-05-25 John Aakerlund Elektronisk stickpropp och adapterkabel, samt generellt elektroniskt brytelement i väggströmställare och elektroniska säkringar med överströmskydd för allström mm
US7658947B2 (en) 2004-06-25 2010-02-09 Kimberly-Clark Worldwide, Inc. Thermo-gelling composition
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
TW201309346A (zh) 2011-01-05 2013-03-01 Hospira Inc 噴霧乾燥萬古黴素
SG11201500994SA (en) 2012-08-10 2015-03-30 Osio Corp D B A Yolia Health Contact lens use in the treatment of an ophthalmologic condition
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
DK3272361T3 (da) 2013-10-22 2020-01-27 Medac Ges Fuer Klinische Spezialpraeparate Mbh Fremgangsmåde til fremstilling af en frysetørret farmaceutisk sammensætning med indhold af mitomycin c

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6509059A (no) * 1964-07-22 1966-01-24
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
GB8426922D0 (en) * 1984-10-24 1984-11-28 Sandoz Ltd Galenic formulation
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
ATE88352T1 (de) * 1988-02-26 1993-05-15 Genentech Inc Humanes relaxinpraeparat.
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US5624962A (en) * 1993-04-16 1997-04-29 Wakamoto Pharmaceutical Co., Ltd. Aqueous drug composition having property of reversible thermosetting gelation

Also Published As

Publication number Publication date
AU7862994A (en) 1996-05-06
NO971683D0 (no) 1997-04-11
US5756552A (en) 1998-05-26
WO1996011672A1 (fr) 1996-04-25
AU684558B2 (en) 1997-12-18
FI971533A0 (fi) 1997-04-11
EP0782850A1 (en) 1997-07-09
KR100215739B1 (ko) 1999-08-16
EP0782850A4 (en) 1998-03-04
FI971533A (fi) 1997-04-11
KR970705978A (ko) 1997-11-03

Similar Documents

Publication Publication Date Title
NO971683L (no) Lyofilisert farmasöytisk preparat som gjör vandige medikamentblandinger reversibelt termogelatinerende
YU46012B (sh) Postupak za izradu vodenih gelirajućih rastvora derivata arilpropionske kiseline koji mogu da se resporbuju kroz kožu
NO973730L (no) Faste virkestofftilberedninger
NO974618L (no) Farmasöytiske preparater for intranasal administrasjon
NO965012L (no) Farmasöytisk preparat som omfatter glukagon
CN1195524A (zh) 药物制剂
SK12993A3 (en) Pharmaceutical composition of florfenicol
NZ501950A (en) Medicinal compositions for application to mucosa
DE69633018D1 (de) Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
NO893239L (no) Farmasoeytisk preparat for behandling av diabetes mellitus.
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
ATE311227T1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
NO974693L (no) Farmasöytisk preparat inneholdende N-klorfenylkarbamater, N-klorfenyltiokarbamater og N-fosfonoglycin-derivater for å inhibere vekst av cancer og virus i pattedyr
CA2336945A1 (en) Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
SE8804628D0 (sv) New compounds
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
DE69531736D1 (de) Oxytetracyclin enthaltendes arzneimittel mit verzögerter wirksoffabgabe
SE8902458D0 (sv) Laekemedelskomposition
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
NO20013117L (no) Kosmetisk preparat av spraytype og matriks anvendt i preparatet for dermal tilforsel
FI932654A (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
SE8900751L (sv) Farmaceutisk komposition